Given that PI3K/mTOR inhibitors repress aerobic glycolysis in EGFR-mutated LAD cells, further studies are warranted to understand how cancer cell metabolism is regulated and to develop more effective therapeutic agents specifically targeted to the metabolic pathways that can limit cancer growth. This evidence concerns the gene EGFR and cancer.